Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribociclib (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 19 Jul 2023 Results of pooled data from NCT01898845, NCT01237236, NCT01872260, NCT01958021,NCT02422615, NCT02278120 to determine PK, safety and efficacy of Ribociclib in combination with endocrine therapy (ET) presented in the Journal of Clinical Pharmacology
    • 01 Jan 2018 Results assessing maximum tolerated dose and recommended dose for expansion, published in the Cancer Science.
    • 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top